Norwegian biotech firm Nordic Nanovector has actually unified forces along with US firm AREVA Med to investigate the potential of lead-212 conjugated anti-CD37 antibody with treating leukemias, it has actually been announced.
Under the regards to the agreement, Nordic Nanovector will certainly give its chimeric anti-CD37 antibody (NNV003) and its understanding in antibody radionuclide conjugate (ARC) development, while AREVA Med will certainly give understanding in the production of 212pb.
Nordic Nanovector’s chief scientific officer, Jostein Dahle, said: “The CD37 antigen is expressed about the surface of numerous hematological cancer cells, consisting of leukemia cells, creating an crucial focus on with ARC-based therapies.
“Our long term approach is focused about structure a pipeline of items that leverages our understanding in CD37-targeting and ARCs, combined, where necessary, along with therapeutic payloads and complementary understanding from partners such as AREVA Med. We are excited to start this brand-new collaboration and to evaluate the potential of this novel 212Pb-ARC with treating leukemias.”
Preclinical studies to figure out the very first security and efficacy profile of the novel anti-CD37 212pb-ARC will certainly be administered at AREVA Med’s facility in Plano, Texas, USA.
Nanovector has actually the selection to license any kind of resulting ARCs with additional progress and AREVA Med has actually the selection to license the usage of CD37-targeting antibodies with its very own purposes. The two business will certainly add to the collaboration, which will certainly likewise reward from grant funding awarded in February 2016 to Nordic Nanovector from the Study Council of Norway’s user-steered research-based innovation program, Brukerstyrt innovasjonsarena.
